Detection threshold of single SPIO-labeled cells with FIESTA

Imaging Research Laboratories, Robarts Research Institute, London, Canada.
Magnetic Resonance in Medicine (Impact Factor: 3.4). 02/2005; 53(2):312-20. DOI: 10.1002/mrm.20356
Source: PubMed

ABSTRACT MRI of superparamagnetic iron oxide (SPIO)-labeled cells has become a valuable tool for studying the in vivo trafficking of transplanted cells. Cellular detection with MRI is generally considered to be orders of magnitude less sensitive than other techniques, such as positron emission tomography (PET), single photon emission-computed tomography (SPECT), or optical fluorescence microscopy. However, an analytic description of the detection threshold for single SPIO-labeled cells and the parameters that govern detection has not been adequately provided. In the present work, the detection threshold for single SPIO-labeled cells and the effect of resolution and SNR were studied for a balanced steady-state free precession (SSFP) sequence (3D-FIESTA). Based on the results from both theoretical and experimental analyses, an expression that predicts the minimum detectable mass of SPIO (m(c)) required to detect a single cell against a uniform signal background was derived: m(c) = 5v/(K(fsl) x SNR), where v is the voxel volume, SNR is the image signal-to-noise ratio, and K(fsl) is an empirical constant measured to be 6.2 +/- 0.5 x 10(-5) microl/pgFe. Using this expression, it was shown that the sensitivity of MRI is not very different from that of PET, requiring femtomole quantities of SPIO iron for detection under typical micro-imaging conditions (100 microm isotropic resolution, SNR = 60). The results of this work will aid in the design of cellular imaging experiments by defining the lower limit of SPIO labeling required for single cell detection at any given resolution and SNR.

  • [Show abstract] [Hide abstract]
    ABSTRACT: This article describes a new acquisition and reconstruction concept for positive contrast imaging of cells labeled with superparamagnetic iron oxides (SPIOs). Overcoming the limitations of a negative contrast representation as gained with gradient echo and fully balanced steady state (bSSFP), the proposed method delivers a spatially localized contrast with high cellular sensitivity not accomplished by other positive contrast methods. Employing a 3D radial bSSFP pulse sequence with half-echo sampling, positive cellular contrast is gained by adding artificial global frequency offsets to each half-echo before image reconstruction. The new contrast regime is highlighted with numerical intravoxel simulations including the point-spread function for 3D half-echo acquisitions. Furthermore, the new method is validated on the basis of in vitro cell phantom measurements on a clinical MRI platform, where the measured contrast-to-noise ratio (CNR) of the new approach exceeds even the negative contrast of bSSFP. Finally, an in vivo proof of principle study based on a mouse model with a clear depiction of labeled cells within a subcutaneous cell islet containing a cell density as low as 7 cells/mm3 is presented. The resultant isotropic images show robustness to motion and a high CNR, in addition to an enhanced specificity due to the positive contrast of SPIO-labeled cells. Copyright © 2014 John Wiley & Sons, Ltd.
    NMR in Biomedicine 11/2014; DOI:10.1002/nbm.3229 · 3.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Islet transplantation is one of the most promising and effective therapies for restoring normoglycemia in type 1 diabetic (T1D) patients but islet engraftment is one of the main obstacles hampering long-term success. Monitoring graft loss, caused either by immunological or non-immunological events, occurring in the first phase after transplantation and at later stages of patient’s life is a very important issue. Among the imaging approaches previously applied Magnetic Resonance Imaging (MRI) monitoring of islets fate following labeling with superparamagnetic iron oxide agents resulted promising. Aim of this study was to translate into patients the method of islet labeling and MRI monitoring developed in our preclinical setting, and to compare imaging results with graft clinical outcome. Three T1D patients and one non-diabetic patient undergoing auto-transplantation following subtotal pancreasectomy received Endorem®-labeled islets. Patients were monitored by MRI and metabolically (HbA1C, exogenous insulin requirement and C-peptide, TEF) at 1, 3, 7 days following transplantation and once a month up to ten months. Labeled transplanted islets appeared as hypointense areas scattered within the liver parenchyma, whose absolute number at 24hr after transplantation reflected the labeling efficiency. In Pt#1 and 3 with good mid-term graft function, MRI follow-up showed an important early loss of hypointense spots followed by a slow and progressive disappearance at later time points. Graft loss of function in Pt#2 4 weeks after transplantation was associated with the complete disappearance of all hypointense signals. The auto-transplanted patient stably insulin free, showed no significant signal reduction during the first 3 days, followed by loss of spots similar to Pt with good mid-term graft function. These results suggest that MRI monitoring of islet transplantation at early time points could represent a meaningful read-out for helping in predicting transplant failure or success, but its relevance for mid-/long-term islet function assessment appears evanescent.
    Cell Transplantation 08/2014; DOI:10.3727/096368914X684060 · 3.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nanotechnology plays an increasingly important role not only in our everyday life (with all its benefits and dangers) but also in medicine. Nanoparticles are to date the most intriguing option to deliver high concentrations of agents specifically and directly to cancer cells; therefore, a wide variety of these nanomaterials has been developed and explored. These span the range from simple nanoagents to sophisticated smart devices for drug delivery or imaging. Nanomaterials usually provide a large surface area, allowing for decoration with a large amount of moieties on the surface for either additional functionalities or targeting. Besides using particles solely for imaging purposes, they can also carry as a payload a therapeutic agent. If both are combined within the same particle, a theranostic agent is created. The sophistication of highly developed nanotechnology targeting approaches provides a promising means for many clinical implementations and can provide improved applications for otherwise suboptimal formulations. In this review we will explore nanotechnology both for imaging and therapy to provide a general overview of the field and its impact on cancer imaging and therapy.
    Critical reviews in oncogenesis 01/2014; 19(3-4):143-176. DOI:10.1615/CritRevOncog.2014011601

Full-text (2 Sources)

Available from
May 22, 2014